SEC Filing Summary for Camp4 Therapeutics Corp

This filing details a Form 4 filed by Josh Mandel-Brehm, Chief Executive Officer and Director of Camp4 Therapeutics Corp. On December 11, 2025, Mandel-Brehm acquired 425,000 stock options with a right to buy common stock. These options have an exercise price of $6.01 and an expiration date of December 10, 2035. The options vest starting December 1, 2025, with one-third vesting on the first anniversary and the remainder vesting monthly over the subsequent 24 months, contingent upon continued service. The filing indicates a post-transaction ownership of 425,000 shares represented by these options.